



9 November 2020

Sydney, Australia

Unlisted Convertible Note Options Expiring 30 November 2020

Sydney, 9 November 2020: Nyrada Inc (ASX: NYR) wishes to advise that the following unlisted Convertible Note Options are due to expire on 30 November 2020.

ASX Code	Number	Escrow Term	Description
NYRAD	695,199	9 Jan 2021	Unlisted Convertible Note Options exercisable at \$0.20, expiring on 30 November 2020.
NYRAF	1,030,457	9 Jan 2022	Unlisted Convertible Note Options exercisable at \$0.20, expiring on 30 November 2020.

If the Convertible Note Options are exercised prior to the expiry date, the Class A Common Stock / CDIs issued will be subject to the remaining ASX escrow terms as shown above. Furthermore, the holder may be required to execute new escrow documentation if required by the ASX.

Any participant wishing to exercise their options must forward a completed option exercise form (available from the Company Registry) and payment prior to 5.00pm (AEDT) on the expiry date, with the allotment of securities scheduled to be made on 1 December 2020 (subject to receipt of cleared funds).

About Nyrada Inc

Nyrada is a preclinical stage, drug discovery and development company, specialising in novel small molecule drugs to treat cardiovascular, neurological, and inflammatory/autoimmune diseases. The Company has two main programs, each targeting market sectors of significant size and considerable unmet clinical need. These are a cholesterol lowering drug and a drug to treat brain injury, specifically traumatic brain injury and stroke. Nyrada Inc. ARBN 625 401 818 is a company incorporated in the state of Delaware, USA, and the liability of its stockholders is limited.

-ENDS-

Authorised by Mr John Moore, Non-Executive Chairman, on behalf of the Board.

www.nyrada.com

Investor & Corporate Enquiries:

Prue Kelly
T: 0459 022 445
E: info@nyrada.com

Company Secretary:

David Franks
T: 02 8072 1400
E: David.Franks@automicgroup.com.au

Media Enquiries:

Catherine Strong, Citadel-MAGNUS
T: 02 8234 0111
E: cstrong@citadelmagnus.com